000 | 02003 a2200529 4500 | ||
---|---|---|---|
005 | 20250517235252.0 | ||
264 | 0 | _c20191223 | |
008 | 201912s 0 0 eng d | ||
022 | _a1523-6536 | ||
024 | 7 |
_a10.1016/j.bbmt.2018.08.028 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aIjaz, Awais | |
245 | 0 | 0 |
_aSignificant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. _h[electronic resource] |
260 |
_bBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation _c01 2019 |
||
300 |
_a94-99 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review | ||
650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
650 | 0 | 4 | _aChronic Disease |
650 | 0 | 4 | _aDisease-Free Survival |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGraft vs Host Disease _xmortality |
650 | 0 | 4 |
_aHematologic Neoplasms _xmortality |
650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 | _aTransplantation, Homologous |
700 | 1 | _aKhan, Ali Younas | |
700 | 1 | _aMalik, Saad Ullah | |
700 | 1 | _aFaridi, Warda | |
700 | 1 | _aFraz, Muhammad Asad | |
700 | 1 | _aUsman, Muhammad | |
700 | 1 | _aTariq, Muhammad Junaid | |
700 | 1 | _aDurer, Seren | |
700 | 1 | _aDurer, Ceren | |
700 | 1 | _aRuss, Atlantis | |
700 | 1 | _aParr, Nadia Nunes Cavalcante | |
700 | 1 | _aBaig, Zeeshan | |
700 | 1 | _aSagar, Fnu | |
700 | 1 | _aAli, Zeeshan | |
700 | 1 | _aMcBride, Ali | |
700 | 1 | _aAnwer, Faiz | |
773 | 0 |
_tBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation _gvol. 25 _gno. 1 _gp. 94-99 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bbmt.2018.08.028 _zAvailable from publisher's website |
999 |
_c28815702 _d28815702 |